comprehensive -WSS

comprehensive

author：comprehensive 2025-09-05 11:32:24 - browse：944

Under the Affordable Care Act, health insurers are required to cover all costs associated with preventive care — including PrEP, or pre-exposure prophylactic treatment for HIV. But now all preventive care coverage is under threat, thanks to a lawsuit filed by employers who believe they shouldn’t be required to pay for care that violates their religious beliefs.

While coverage for PrEP access is largely unchanged as the court case makes its way through the legal system, Richard Hughes IV, a partner with the law firm Epstein Becker Green, says that protecting the status quo isn’t enough. For instance, currently you have to jump through extra hoops to get long-acting injectable PrEP covered by insurance.

But Hughes has a better idea for how to not only protect but also expand access to PrEP.

On this episode of the “First Opinion Podcast,” I spoke to Hughes about his proposal, why access to PrEP has never been what it should be, the Supreme Court’s current approach to health care, and more.

“If a provider has a bad experience with a previous patient experiencing non-coverage, they might say to the next patient, ‘Well, I’m not sure this is going to be covered.’ And that can be really discouraging,” Hughes said. “What we really need to create that clarity for patients is for this law to be upheld, for the recommendations to be clear, and for providers to have the assurance that they will be covered by payers.”

Our conversation was based on his recent First Opinion op-ed, “How to protect PrEP coverage, no matter what happens in Braidwood v. Becerra.”

Be sure to sign up for the weekly “First Opinion Podcast” on Apple Podcasts, Stitcher, Google Play, or wherever you get your podcasts.

And if you have any feedback for us — First Opinion authors to feature on the podcast, kudos, or darts — email us at [email protected] and please put “podcast” in the subject line.

Previous article： State Dept. review finds Biden bears some blame for Afghanistan failures
Next article： Why the world’s most expensive drug might be worth the price

focus

entertainment

WSS

WATCH: Why do bright lights make us see spots?

Adam's Biotech Scorecard: A closer look at Viking Therapeutics, PDS Biotech

FDA approves updated Covid vaccines

Diverse clinical trials: Why aren’t we there yet?

White House touts steps to stem shortages of cancer treatments

A common UTI test for kids haunts adults as a traumatic 'nightmare'

entertainment

comprehensive

hotspot

BioMarin wins approval for gene therapy to treat hemophilia A

Readout Newsletter: Blackstone Life Sciences, Merck, Bluebird Bio

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

Decaf coffee targeted by food safety group under obscure FDA rule

Alkermes shareholders re

The Readout: Lenmeldy, GLP

How one medical school became remarkably diverse

There's no autism epidemic. It's an autism diagnosis epidemic

Sports medicine is finally prioritizing gender equality

FDA proposes changes to key medical devices approval pathway

explore

Covid vaccine financial winners and losers, from Pfizer to Novavax

Long Covid needs a new name — and a new frame

FDA panel endorses Alnylam’s heart drug — after picking it apart

FDA's naming rule on biosimilars has undermined competition

Will the IRA bring competition to the biologics market?

Telehealth for opioid use disorder is lifesaving

focus

entertainment

entertainment

hotspot